Consignor Eddie Woods stood in the back ring March 13, trying his best to articulate the thoughts whipping through his mind ...
KRRO-110 is the first RNA editing development candidate from Korro’s proprietary OPERA TM platform and is currently being evaluated in the Phase 1/2a REWRITE clinical study for AATD. Dosing of the ...
We may be starting to get a grasp on what kick-started life on Earth – and it could help us search for it on other planets ...
H.C. Wainwright raised the firm’s price target on ProQR Therapeutics (PRQR) to $12 from $10 and keeps a Buy rating on the shares. The firm says ...
“In general, we have not recommended boosters because there is no clear evidence that people need it. But there probably is ...